Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 103

Sort by

Sort Order Select

Journal Articles

Discovery of JNJ-88549968, a Novel, First-in-Class CALRmutxCD3 T-Cell Redirecting Antibody for the Treatment of Myeloproliferative Neoplasms

Blood (2023) 142 (Supplement 1): 1777.

https://doi.org/10.1182/blood-2023-173430

Published: 2023

Journal Articles

Individualized Dosing of Ropeginterferon Alfa-2b Ensures Optimal Response in Patients with Low-Risk Polycythemia Vera (PV)

Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Liliya Sivcheva, Jiri Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans Hasselbalch, Robert Kralovics, Jean-Jacques Kiladjian

Blood (2023) 142 (Supplement 1): 4563.

https://doi.org/10.1182/blood-2023-173499

Published: 2023

Journal Articles

Genetic basis and molecular profiling in myeloproliferative neoplasms

Damien Luque Paz, Robert Kralovics, Radek C. Skoda

Blood (2023) 141 (16): 1909–1921.

https://doi.org/10.1182/blood.2022017578

Published: 2023

Journal Articles

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms

Blood (2023) 141 (8): 917–929.

https://doi.org/10.1182/blood.2022016846

Published: 2023

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Long-Term Ropeginterferon Alfa-2b Treatment in Patients with Low-Risk and High-Risk Polycythemia Vera (PV)

Jean-Jacques Kiladjian, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiří Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans Carl Hasselbalch, Robert Kralovics, Heinz Gisslinger

Blood (2022) 140 (Supplement 1): 9663–9664.

https://doi.org/10.1182/blood-2022-156889

Published: 2022

Journal Articles

Polycythemia Vera Patients Respond Better to Ropeginterferon Alfa-2b Than HU/BAT Irrespective of Pretreatment or Mutational Status; Results from 5 Years' Treatment in a Randomized, Controlled Setting in the PROUD-PV/Continuation-PV Trials

Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiri Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans C. Hasselbalch, Robert Kralovics, Jean-Jacques Kiladjian

Blood (2021) 138 (Supplement 1): 3660.

https://doi.org/10.1182/blood-2021-152328

Published: 2021

Journal Articles

Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor

Ruochen Jia, Thomas Balligand, Vasyl Atamanyuk, Harini Nivarthi, Erica Xu, Leon Kutzner, Jakob Weinzierl, Audrey Nedelec, Stefan Kubicek, Roman Lesyk, Oleh Zagrijtschuk, Stefan N. Constantinescu, Robert Kralovics

Blood (2021) 137 (14): 1920–1931.

https://doi.org/10.1182/blood.2020006264

Published: 2021

Includes: Supplemental data

Journal Articles

Germline genetic factors influence the outcome of interferon-α therapy in polycythemia vera

Roland Jäger, Heinz Gisslinger, Elisabeth Fuchs, Edith Bogner, Jelena D. Milosevic Feenstra, Jakob Weinzierl, Fiorella Schischlik, Bettina Gisslinger, Martin Schalling, Michael Zörer, Kurt Krejcy, Christoph Klade, Robert Kralovics

Blood (2021) 137 (3): 387–391.

https://doi.org/10.1182/blood.2020005792

Published: 2021

Includes: Supplemental data

Journal Articles

Overexpression of PD-L1 Correlates with JAK2 -V617F Mutational Burden and Is Associated with Chromosome 9p Uniparental Disomy in MPN

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-137447

Published: 2020

Journal Articles

Ifnα Attenuates the Disease Phenotype and Extends Survival in Mouse Models of MPN

Harini Nivarthi, PhD, Andrea Majoros, PhD, Eva Hug, PhD, Ruochen Jia, PhD, Sarada Achyutuni, Roland Jäger, PhD, Raimund Holly, Beatrice Grabner, Felix Rosebrock, Shin-Jye Lee, Chung-Wei Lee, Robert Kralovics, PhD

Blood (2020) 136 (Supplement 1): 53.

https://doi.org/10.1182/blood-2020-138813

Published: 2020

Journal Articles

Phenotyping of Disease-Initiating CD34 + /CD38 ─ Stem Cells in BCR-ABL1 ─ MPN Reveals Expression of Multiple Cytokine Receptors and Resistance-Related Antigens

Blood (2020) 136 (Supplement 1): 53.

https://doi.org/10.1182/blood-2020-140477

Published: 2020

Journal Articles

Co-Expression of JAK2-V617F and Calr-del52 In Vivo Enhances Myeloproliferative Phenotype in Mice and Does Not Influence Competitive Fitness of Hematopoietic Stem Cells

Andrea Majoros, PhD, Harini Nivarthi, PhD, Ruochen Jia, PhD, Roland Jäger, PhD, Sarada Achyutuni, Christina M. Schueller, Robert Kralovics, PhD

Blood (2020) 136 (Supplement 1): 20.

https://doi.org/10.1182/blood-2020-139996

Published: 2020

Journal Articles

Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension

Heinz Gisslinger, MD, Christoph Klade, PhD, Pencho Georgiev, MD, Dorota Krochmalczyk, MD, Liana Gercheva-Kyuchukova, MD, Miklos Egyed, MD, Petr Dulicek, MD, Árpád Illés, MD PhD, Halyna Pylypenko, MD, Lylia Sivcheva, MD, Jiří Mayer, Vera Yablokova, MD, Kurt Krejcy, MD, Victoria Empson, MSc, Hans C. Hasselbalch, MD, Robert Kralovics, PhD, Jean Jacques Kiladjian, MD PhD

Blood (2020) 136 (Supplement 1): 33.

https://doi.org/10.1182/blood-2020-136973

Published: 2020

Journal Articles

Germline Genetic Factors Affecting Interferon Alpha Therapy in Polycythemia Vera

Roland Jäger, PhD, Elisabeth Fuchs, Edith Bogner, Jelena D. Milosevic Feenstra, PhD, Kurt Krejcy, MD, Christoph Klade, PhD, Michael Zoerer, PhD, Heinz Gisslinger, MD, Robert Kralovics, PhD

Blood (2019) 134 (Supplement_1): 1685.

https://doi.org/10.1182/blood-2019-130139

Published: 2019

Journal Articles

Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study

Jean-Jacques Kiladjian, MD PhD, Christoph Klade, PhD, Pencho Georgiev, MD, Dorota Krochmalczyk, MD, Liana Gercheva-Kyuchukova, MD, Miklos Egyed, Viktor Rossiev, MD, Petr Dulicek, MD, Árpád Illés, MD D.Sc, Halyna Pylypenko, MD, Lylia Sivcheva, MD, Jiri Mayer, MD, Vera Yablokova, MD, Kurt Krejcy, MD, Hans Hasselbalch, MD, Robert Kralovics, PhD, Heinz Gisslinger, MD

Blood (2019) 134 (Supplement_1): 553.

https://doi.org/10.1182/blood-2019-122233

Published: 2019

Journal Articles

Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms

Blood (2019) 134 (2): 199–210.

https://doi.org/10.1182/blood.2019000519

Published: 2019

Includes: Supplemental data

Journal Articles

Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants

Blood (2019) 133 (25): 2669–2681.

https://doi.org/10.1182/blood-2018-09-874578

Published: 2019

Includes: Supplemental data

Journal Articles

CDK6 coordinates JAK2 V617F mutant MPN via NF-κB and apoptotic networks

Iris Z. Uras, Barbara Maurer, Harini Nivarthi, Philipp Jodl, Karoline Kollmann, Michaela Prchal-Murphy, Jelena D. Milosevic Feenstra, Markus Zojer, Sabine Lagger, Reinhard Grausenburger, Beatrice Grabner, Raimund Holly, Anoop Kavirayani, Christoph Bock, Heinz Gisslinger, Peter Valent, Robert Kralovics, Veronika Sexl

Blood (2019) 133 (15): 1677–1690.

https://doi.org/10.1182/blood-2018-08-872648

Published: 2019

Includes: Supplemental data

Journal Articles

Effect of Ropeginterferon Alfa-2b in Prefibrotic Primary Myelofibrosis

Heinz Gisslinger, Bettina Gisslinger, Martin Schalling, MSc, Kurt Krejcy, PhD, Rudolf S. Widmann, PhD BSc, Robert Kralovics, PhD, Maria-Theresa Krauth, MD

Blood (2018) 132 (Supplement 1): 3029.

https://doi.org/10.1182/blood-2018-99-119268

Published: 2018

Journal Articles

Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results

Blood (2018) 132 (Supplement 1): 3030.

https://doi.org/10.1182/blood-2018-99-118584

Published: 2018

NARROW

Discovery of JNJ-88549968, a Novel, First-in-Class CALRmutxCD3 T-Cell Redirecting Antibody for the Treatment of Myeloproliferative Neoplasms

Individualized Dosing of Ropeginterferon Alfa-2b Ensures Optimal Response in Patients with Low-Risk Polycythemia Vera (PV)

Genetic basis and molecular profiling in myeloproliferative neoplasms

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms

Efficacy and Safety of Long-Term Ropeginterferon Alfa-2b Treatment in Patients with Low-Risk and High-Risk Polycythemia Vera (PV)

Polycythemia Vera Patients Respond Better to Ropeginterferon Alfa-2b Than HU/BAT Irrespective of Pretreatment or Mutational Status; Results from 5 Years' Treatment in a Randomized, Controlled Setting in the PROUD-PV/Continuation-PV Trials

Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor

Germline genetic factors influence the outcome of interferon-α therapy in polycythemia vera

Overexpression of PD-L1 Correlates with JAK2 -V617F Mutational Burden and Is Associated with Chromosome 9p Uniparental Disomy in MPN

Ifnα Attenuates the Disease Phenotype and Extends Survival in Mouse Models of MPN

Phenotyping of Disease-Initiating CD34 + /CD38 ─ Stem Cells in BCR-ABL1 ─ MPN Reveals Expression of Multiple Cytokine Receptors and Resistance-Related Antigens

Co-Expression of JAK2-V617F and Calr-del52 In Vivo Enhances Myeloproliferative Phenotype in Mice and Does Not Influence Competitive Fitness of Hematopoietic Stem Cells

Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension

Germline Genetic Factors Affecting Interferon Alpha Therapy in Polycythemia Vera

Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study

Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms

Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants

CDK6 coordinates JAK2 V617F mutant MPN via NF-κB and apoptotic networks

Effect of Ropeginterferon Alfa-2b in Prefibrotic Primary Myelofibrosis

Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only